Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Lin C., Taylor M., Boni V., Brunsvig P. F., Geater S. L., Salvagni S., ...More

43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.413, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 29
  • City: Munich
  • Country: Germany
  • Page Numbers: pp.413
  • Istanbul University Affiliated: Yes